Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases

Neuropeptides

Volumn 44, Issue 2, 2010, Pages 69-75

  Adam, Albert ^a   Leclair, Patrick ^a   Montpas, Nicolas ^a   Koumbadinga, Gérémy Abdull ^b   Bachelard, Hélène ^b   Marceau, François ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme; Bradykinin metabolism; Diabetes; Neutral endopeptidase

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRILAT; INSULIN; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR FLUID; GENETIC VARIABILITY; HEART MUSCLE; HYDROLYSIS; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; RAT; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; HEART; INSULIN; MALE; MYOCARDIUM; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

RATTUS;

EID: 77049099787     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.09.004     Document Type: Article

References (37)

1. Blais Jr. C., Drapeau G., Raymond P., Lamontagne D., Gervais N., Venneman I., and Adam A. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. Heart Circ. Physiol. 273 (1997) H2263-H2271
2. Bray G.A. The Zucker fatty rat: a review. Fed. Proc. 36 (1977) 148-153
3. Brunning P., Holmquist B., and Riordan J.F. Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry 22 (1983) 103-110
4. Carvalho C.R.O., Thirone A.P.C., Gontijo J.A.R., Velloso L.A., and Saad M.J.A. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46 (1997) 1950-1957
5. Costerousse O., Allegrini J., Huang H., Bounhiko J., and Alhenc-Gelas F. Regulation of ACE gene expression and plasma levels during rat postnatal development. Am. J. Physiol. Endocrinol. Metab. 267 (1994) E745-E753
6. Décarie A., Drapeau G., Closset J., Couture R., and Adam A. Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 15 (1994) 511-518
7. Drimal J., Knezl V., Navarova J., Nedelcevova J., Paulovicova E., Sotnikova R., Snirc V., and Drimal D. Role of inflammatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure. Endocr. Regul. 42 (2008) 129-135
8. Dumoulin M.J., Adam A., Blais Jr. C., and Lamontagne D. Metabolism of bradykinin by the rat coronary bed. Cardiovasc. Res. 38 (1998) 229-236
9. Erdös E.G., and Skidgel R.A. Metabolism of bradykinin by peptidases in health and disease. In: Farmer S.G. (Ed). The Kinin System (1997), Academic Press, San Diego, CA 111-141
10. Gazis A., Page S.R., and Cockcroft J.R. ACE inhibitors, diabetes and cardiovascular disease. Diabetologia 41 (1998) 595-597
11. Henriksen E.J., and Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44 (1995) 267-272
12. HOPE investigators, 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153.
13. Lamarre N.S., Ruggieri M.R., Braveman A.S., Gerstein M.I., and Mydlo J.H. Effect of obese and lean Zucker rat sera on human and rat prostate cancer cells: implications in obesity-related prostate tumor biology. Urology 69 (2007) 191-195
14. Le Moual H., Devault A., Roques B.P., Crine P., and Boileau G. Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase 24.11. J. Biol. Chem. 266 (1991) 15670-15674
15. Leeb-Lundberg L.M., Marceau F., Müller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 (2005) 27-77
16. Linz W., Wiemer G., Gohlke P., Unger T., and Schölkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47 (1995) 25-49
17. Liu R.H., Mizuta M., Kurose T., and Matsukura S. Early events involved in the development of insulin resistance in Zucker fatty rats. Int. J. Obesity 26 (2002) 318-326
18. Mackay A.R., Ballin M., Pelina M.D., Farina A.R., Nason A.M., Hartzler J.L., and Thorgeirsson U.P. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 12 (1992) 168-184
19. Moore J.W., and Pearson R.G. Complex reactions. In: Moore J.W., and Pearson R.G. (Eds). Kinetics and Mechanism. third ed. (1981), Wiley, New York 284-296
20. Naruse K., Rask-Madsen C., Takahara N., Ha S.W., Suzuma K., Way K.J., Jacobs J.R., Clermont A.C., Ueki K., Ohshiro Y., Zhang J., Goldfine A.B., and King G.L. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55 (2006) 691-698
21. Papapetropoulos A., Antonov A., Virmani R., Kolodgie F.D., Munn D.H., Marczin N., Ryan J.W., Gerrity R.G., and Catravas J.D. Monocyte- and cytokine-induced downregulation of angiotensin-converting enzyme in cultured human and porcine endothelial cells. Circ. Res. 79 (1996) 512-523
22. Prechel M.M., Orawski A.T., Maggiora L.L., and Simmons W.H. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J. Pharmacol. Exp. Ther. 275 (1995) 1136-1142
23. Ramchandran R., Kasturi S., Douglas J.G., and Sen I. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am. J. Physiol. Heart Circ. Physiol. 271 (1996) H744-H751
24. Raut R., Rouleau J.L., Blais Jr. C., Gosselin H., Molinaro G., Sirois G.M., Lepage Y., Crine P., and Adam A. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am. J. Physiol. Heart Circ. Physiol. 276 (1999) H1769-H1779
25. Ryan J.W., Berryer P., Chung A.Y.K., and Sheffy D.H. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J. Pharmacol. Exp. Ther. 269 (1994) 941-947
26. Saijonmaa O., Nyman T., and Fyhrquist F. Downregulation of angiotensin-converting enzyme by tumor necrosis factor-α and interleukin-1β in cultured human endothelial cells. J. Vasc. Res. 38 (2001) 370-378
27. Saijonmaa O., Nyman T., Kosonen R., and Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H885-H891
28. Schernthaner G., Schwarzer C., Kuzmits R., Müller M.M., Klemen U., and Freyler H. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease. J. Clin. Pathol. 37 (1984) 307-312
29. Tatti P., Pahor M., Byington P.R., Di Mauro P., Guarisco R., Strollo G., and Strollo F. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (1998) 597-603
30. Trippodo N.C., Robl J.A., Asaad M.M., Fox M., Panchal B.C., and Schaeffer T.R. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. 11 (1998) 363-372
31. Tschöpe C., Gavriluk V., Reinecke A., Seidl U., Riester U., Hilgenfeldt U., Ritz E., and Unger T. Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology 33 (1996) 344-348
32. Uehara M., Kishikawa H., Isami S., Kisanuki K., Ohkubo Y., Miyamura N., Miyata T., Yano T., and Shichiri M. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37 (1994) 300-307
33. van Dijk D.J., Boner G., Giler S., and Erman A. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat. J. Renin Angiot. Aldo. Syst. 2 (2001) 193-198
34. Villard E., Alonso A., Agrapart M., Challah M., and Soubrier F. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J. Biol. Chem. 273 (1998) 25191-25197
35. Wallenstein S., Zucker C.L., and Fleis J.L. Some statistical methods useful in circulation research. Circ. Res. 47 (1990) 1-9
36. Wautier J.L., Wautier M.P., Schmidt A.M., Anderson G.M., Hori O., Zoukourian C., Capron L., Chappey O., Yan S.D., Brett J., Guillausseau P.J., and Stern D. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 91 (1994) 7742-7746
37. Ye M., Wysocki J., Naaz P., Salabat M.R., LaPointe M.S., and Batlle D. Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension 43 (2004) 1120-1125